(16322749), M. A. Y., (16515247), A. A. H., (16515249), R. M. H., (16515250), A. M. B., (16515253), A. M. A., (9072038), P. C., & (16328993), A. J. N. (2021). Dasatinib versus nilotinib as upfront therapy for treatment naïve chronic myeloid leukemia chronic phase.
توثيق أسلوب شيكاغو (الطبعة السابعة عشر)(16322749), Mohamed A. Yassin, Anas A. Hamad (16515247), Radwa M. Hussein (16515249), Ahmed M. Basha (16515250), Ahmad M. Adel (16515253), Prem Chandra (9072038), و Abdulqadir J. Nashwan (16328993). Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase. 2021.
توثيق جمعية اللغة المعاصرة MLA (الإصدار التاسع)(16322749), Mohamed A. Yassin, et al. Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase. 2021.